Life Sciences Tools and Services
Company Overview of Sequenom Inc.
Sequenom, Inc., a life sciences company, develops and commercializes molecular diagnostics testing services for the women's health and oncology markets in the United States and internationally. The company provides molecular based laboratory developed tests (LDTs) comprising MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; and VisibiliT LDT, a NIPT to detect fetal chromosomal abnormalities by determining the relative amount of chromosomal material present in circulating cell-free DNA in a maternal blood sample. It also offers MaterniT21 GENOME test to detect genome-wide genomic deletions or duplications; HerediT cystic fibrosis (CF) LDT, a ca...
3595 John Hopkins Court
San Diego, CA 92121
Founded in 1994
Key Executives for Sequenom Inc.
Chairperson, President and Secretary
Senior Vice President, General Counsel and Secretary
Senior Vice President of Corporate Governance and Regulatory Affairs
Chief Medical Officer and Senior Vice President
Executive Vice President, Treasurer and Director
Compensation as of Fiscal Year 2016.
Sequenom Inc. Key Developments
Sequenom Inc. Files Form 15
Sep 23 16
Sequenom Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended. The par value of the company's common stock was $0.001 per share.
Sequenom Inc. Announces Amendments to Articles of Incorporation and Bylaws
Sep 7 16
In connection with the closing of the Merger Sequenom Inc. and Wells Fargo Bank, National Association entered into a First Supplemental Indenture, dated as of September 7, 2016 to the Indenture, dated as of September 17, 2012, between Sequenom and Wells Fargo Bank, National Association, relating to the company's 5.00% Convertible Senior Notes due 2017, and a First Supplemental Indenture, dated as of September 7, 2016 to the Indenture, dated as of June 9, 2015, between the company and the Trustee, relating to the company's 5.00% Convertible Exchange Senior Notes due 2018.
Sequenom Inc. Announces Executive Changes
Sep 7 16
Sequenom Inc. entered into an Agreement and Plan of Merger with Laboratory Corporation of America Holdings and Savoy Acquisition Corp. and direct wholly owned subsidiary of LabCorp. Pursuant to the Merger Agreement, effective as of the Effective Time, on September 7, 2016, each of Kenneth F. Buechler, Myla Lai-Goldman, Richard A. Lerner, Ronald M. Lindsay, David Pendarvis, Catherine J. Mackey, Charles P. Slacik and Dirk van den Boom resigned as a director of the Company and from any committees of the Company's Board of Directors on which they then served. In addition, pursuant to the Merger Agreement and effective as of immediately after the Effective Time, on September 7, 2016, Glenn A. Eisenberg, F. Samuel Eberts III, Sandra D. van der Vaart, William B. Haas and Benjamin R. Miller were appointed to the Board of Directors of the Company. Further, pursuant to the Merger Agreement, effective as of the Effective Time, on September 7, 2016, F. Samuel Eberts III became Chairperson, President and Secretary of the Company, replacing Dirk van den Boom as Chief Executive Officer, President and principal executive officer of the Company, and Glenn A. Eisenberg became Executive Vice President and Treasurer of the Company, replacing Carolyn D. Beaver as Senior Vice President and Chief Financial Officer and principal financial and accounting officer of the Company. Each of Glenn A. Eisenberg and F. Samuel Eberts III is an officer of LabCorp.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 27, 2016